2003 Dec 12 [updated 2023 Oct 19]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024.
PMID:20301300
A-type lamin-linked lipodystrophies.
Vigouroux C, Capeau J.
Novartis Found Symp. 2005;264:166-77; discussion 177-82, 227-30.
PMID:15773753
The metabolomic plasma profile of patients with Duchenne muscular dystrophy: providing new evidence for its pathogenesis.
Lipodystrophic syndromes due to LMNA mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives.
Vigouroux C, Guénantin AC, Vatier C, Capel E, Le Dour C, Afonso P, Bidault G, Béréziat V, Lascols O, Capeau J, Briand N, Jéru I.
Nucleus. 2018 Jan 1;9(1):235-248. doi: 10.1080/19491034.2018.1456217.
PMID:29578370
Partial Ablation of Non-Myogenic Progenitor Cells as a Therapeutic Approach to Duchenne Muscular Dystrophy.
Gao Z, Lu A, Daquinag AC, Yu Y, Huard M, Tseng C, Gao X, Huard J, Kolonin MG.
Biomolecules. 2021 Oct 15;11(10):1519. doi: 10.3390/biom11101519.
PMID:34680151
Partial lipodystrophy associated with muscular dystrophy of unknown genetic origin.
Carboni N, Brancati F, Cocco E, Solla E, D'Apice MR, Mateddu A, McIntyre A, Fadda E, Mura M, Lattanzi G, Piras R, Maioli MA, Marrosu G, Novelli G, Marrosu MG, Hegele RA.